Sharemaestro Newsreel

Do Options Traders Know Something About AstraZeneca Stock We Don't?

Options traders are showing significant interest in AstraZeneca (AZN) stock, with high implied volatility for the Jan. 15, 2027 $115.00 Call, suggesting expectations of a major price movement. Despite this, AstraZeneca currently holds a Zacks Rank #4 (Sell), and analysts have recently lowered earnings …

These stocks have some of Wall Street’s lowest short interest

[short sale] abluecup Stocks including Apple, Alphabet, Exxon Mobil, and JPMorgan are among the companies with relatively low short interest, according to a screen of stocks with market capitalizations above $2B. The screen includes stocks with short interest between 1% and 2% of shares …

Polen International Equity adds NOK, MUFG; exits AIVAF, RNMBF among Q2 moves

Polen International Equity Strategy outperformed the MSCI ACWI ex-US Index in the second quarter of 2026, returning 21.59% gross and 21.35% net of fees, respectively, versus 14.49% for the benchmark. During the quarter, the fund initiated new positions in ASPEED Technology, Ryohin Keikaku (RYKKF …

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion …

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum …

The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run

Quick Read ISRG is down 31% YTD, but its razor-and-razorblade model now delivers 85% recurring revenue across a fleet of 11,710 da Vinci systems. MDT's Hugo and JNJ's Ottava remain early or pre-commercial, leaving ISRG's $1.73 billion quarterly instruments-and-accessories stream with no real soft-tissue …

Everything You Need to Know About the AstraZeneca–Bristol Myers Squibb Merger Rumors

Reports recently surfaced regarding a potential merger between pharmaceutical giants AstraZeneca and Bristol Myers Squibb, causing significant industry speculation. Although a senior source reportedly debunked these rumors, the prospect of such a large-scale merger between two strong performers raised questions about its strategic rationale …

MERCK & CO INC : ARGUS RESEARCH RAISES TARGET PRICE TO $145 FROM $130

Argus Research has increased its target price for Merck & Co Inc (MRK.N) to $145 from $130. This update reflects the analyst's revised valuation for the pharmaceutical company. The article attributes this information to Reuters.

Nucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration

Collaboration demonstrates how AI-powered Tissue Intelligence is transforming biomarker discovery, translational research, and precision oncology development. TEL AVIV, Israel, August 11, 2026--(BUSINESS WIRE)--Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced …

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"

A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA …

Argus Adjusts Price Target on Merck & Co. to $145 From $130, Keeps Buy Rating

Argus has raised its price target for Merck & Co. (MRK) to $145 from $130, while maintaining a Buy rating on the stock. The adjustment reflects a positive outlook for the pharmaceutical company. This news was published on August 11, 2026, at 08:57 am …

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival …

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development …

Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down …

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Suha Jhaveri, Bill Warren and Jim Wassil added to ILiAD Board of Directors; Antony Blanc appointed Chief Business Officer Appointments deepen vaccine development expertise and enhance global commercial and strategic leadership WESTON, Fla., August 11, 2026--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage …

Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices

Updated program delivers simplified savings, greater benefits transparency, and expanded opportunities for practice growth Introduces new rewards opportunities for customer segments, including first-time APP members, growing practices, and long-standing loyal customers IRVINE, Calif., Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today …

MIUDELLA’s hormone-free IUD requires provider training before use

Organon has launched the Risk Evaluation and Mitigation Strategy (REMS) Program for its hormone-free copper intrauterine device (IUD), MIUDELLA, ahead of its anticipated commercial availability in late 2026. This program mandates training and certification for healthcare providers, healthcare settings, and eligible specialty pharmacies to …

NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

Healthcare Providers, Healthcare Settings, and Participating Pharmacies Can Now Begin Required Training and Certification in Preparation for MIUDELLA's Launch Later This Year JERSEY CITY, N.J., August 11, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions …

Veeva Vault CRM Selected by Eli Lilly and Company

Veeva Systems announced that Eli Lilly and Company (Lilly) has committed to using Veeva Vault CRM globally. This platform is part of the Vault CRM Suite, which supports an "agentic commercial" model leveraging AI to deliver medicines to more patients. Both companies expressed excitement …

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the pharmaceutical giant's already strong immunology portfolio. However, …

Eli Lilly Commits to Veeva CRM to Bring More Medicines to Patients

Veeva Systems announced that Eli Lilly and Company will deploy Veeva Vault CRM globally. This commitment expands their strategic relationship, utilizing Veeva's AI-enabled "agentic commercial" model to help bring new medicines to more patients. The announcement highlights the continued adoption of Veeva's cloud solutions …

Handelsbanken Fonder AB Has $123.19 Million Stake in Gilead Sciences, Inc. $GILD

Handelsbanken Fonder AB decreased its stake in Gilead Sciences by 7.2% in the second quarter, now holding 975,089 shares valued at approximately $123.2 million. Other institutional investors have adjusted their positions, with collective institutional ownership standing at 83.67%. Gilead Sciences reported strong quarterly revenues …

Handelsbanken Fonder AB Has $125.51 Million Stake in Amgen Inc. $AMGN

Handelsbanken Fonder AB increased its stake in Amgen Inc. by 15.7% in the second quarter, now owning 346,596 shares valued at $125.51 million. Several other institutional investors also adjusted their positions in Amgen. The article also provides financial details, recent earnings, dividend information, and …

AbbVie Inc. $ABBV Position Cut by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in AbbVie Inc. by 1.4% during the second quarter, selling 19,132 shares and now owning 1,362,464 shares worth $342.85 million. Despite this, AbbVie remains a "Moderate Buy" among analysts, with recent positive news including the acquisition of Apogee …

Eli Lilly and Company $LLY Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in Eli Lilly and Company (NYSE:LLY) by 3.9% in the second quarter, selling 27,617 shares. Despite this sale, Eli Lilly remains a significant holding for Handelsbanken Fonder AB, representing 2.3% of its portfolio. Other institutional investors, however, increased …

Novo Nordisk and AWS bring agentic AI into drug discovery

Novo Nordisk is expanding its collaboration with AWS to integrate agentic AI into its drug discovery processes, including target identification and therapy design. AWS will serve as Novo Nordisk's preferred cloud provider and strategic AI partner, with a co-innovation hub established in London to …

Amgen Inc. $AMGN Shares Acquired by KMG Fiduciary Partners LLC

KMG Fiduciary Partners LLC increased its stake in Amgen Inc. by 38.9% in the second quarter, bringing its total holdings to 9,856 shares valued at $3.57 million. Institutional investors now own 76.5% of Amgen's stock. The company recently beat earnings expectations, reporting $6.29 EPS …

KMG Fiduciary Partners LLC Acquires 39,875 Shares of Pfizer Inc. $PFE

KMG Fiduciary Partners LLC increased its stake in Pfizer Inc. by 26.4% in the second quarter, purchasing 39,875 shares to bring its total holdings to 190,888 shares valued at approximately $4.6 million. Despite this increased institutional interest, analyst sentiment remains cautious with an average …

KMG Fiduciary Partners LLC Sells 26,888 Shares of Merck & Co., Inc. $MRK

KMG Fiduciary Partners LLC significantly reduced its stake in Merck & Co., Inc. (NYSE:MRK) by selling 26,888 shares, a 50.5% decrease, now holding 26,379 shares valued at $3.39 million. Despite this, institutional investors collectively own 76.07% of Merck's stock, and analysts maintain a "Moderate …

Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific

Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market …

E. Ohman J or Asset Management AB Has $5.66 Million Stock Holdings in Gilead Sciences, Inc. $GILD

E. Ohman J or Asset Management AB significantly reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 88.3% during the second quarter, now holding 44,792 shares valued at $5.66 million. Despite this, other institutional investors have slightly increased their holdings. Analysts currently rate GILD …

Carolina Wealth Advisors LLC Sells 15,954 Shares of Merck & Co., Inc. $MRK

Carolina Wealth Advisors LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 33.2% in the second quarter, selling 15,954 shares and now owning 32,171 shares valued at $4.13 million. The article also details other institutional investor activity, Merck's financial performance including its …

Carolina Wealth Advisors LLC Purchases 7,626 Shares of AbbVie Inc. $ABBV

Carolina Wealth Advisors LLC increased its stake in AbbVie Inc. by 68.6% in the second quarter, purchasing an additional 7,626 shares and bringing its total holdings to 18,741 shares valued at $4.716 million. Other institutional investors have also adjusted their positions in AbbVie, with …

First Trust Advisors LP Lowers Stock Holdings in Novo Nordisk A/S $NVO

Eli Lilly's Foundayo Wins UK Approval

(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory …